These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11311194)

  • 21. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
    Cook JR; Yin D; Alemao E; Drummond M
    Pharmacoeconomics; 2004; 22 Suppl 3():37-48. PubMed ID: 15669152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective management of patients with dyslipidemia.
    Lipsy RJ
    Am J Manag Care; 2003 Feb; 9(2 Suppl):S39-58. PubMed ID: 12597240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel therapeutic approach to dyslipidemia.
    Clearfield MB
    J Am Osteopath Assoc; 2003 Jan; 103(1 Suppl 1):S16-20. PubMed ID: 12572626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
    Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement and management of hyperlipidemia for the primary prevention of coronary heart disease.
    Froom J; Froom P; Benjamin M; Benjamin BJ
    J Am Board Fam Pract; 1998; 11(1):12-22. PubMed ID: 9456442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale for aggressive lipid lowering in high-risk patients.
    Cohen JD
    J Am Osteopath Assoc; 2011 Apr; 111(4 Suppl 3):eS7-12. PubMed ID: 21593473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
    Coukell AJ; Wilde MI
    Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacoeconomics perspectives: payers, providers, and patients.
    Am J Manag Care; 1998 Apr; 4(4 Suppl):S221-4. PubMed ID: 10184937
    [No Abstract]   [Full Text] [Related]  

  • 32. Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials.
    White CW
    Am J Med; 1998 Jul; 105(1A):63S-68S. PubMed ID: 9707270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholesterol management in high-risk patients without heart disease. When is lipid-lowering medication warranted for primary prevention?
    Grundy SM
    Postgrad Med; 1998 Nov; 104(5):117-20, 123-4, 129. PubMed ID: 9823389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preventing coronary artery disease in the West of Scotland: implications for primary prevention.
    Shepherd J
    Am J Cardiol; 1998 Nov; 82(10B):57T-59T. PubMed ID: 9860377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente experience).
    Merenich JA; Lousberg TR; Brennan SH; Calonge NB
    Am J Cardiol; 2000 Feb; 85(3A):36A-42A. PubMed ID: 10695706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of patients with lipid disorders in the primary care setting: new treatment guidelines and their implications.
    Keenan JM
    South Med J; 2003 Mar; 96(3):266-75. PubMed ID: 12659359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholesterol management in the era of managed care.
    Grundy SM
    Am J Cardiol; 2000 Feb; 85(3A):3A-9A. PubMed ID: 10695701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The rationale for combination therapy.
    Rosenson RS
    Am J Cardiol; 2002 Nov; 90(10B):2K-7K. PubMed ID: 12467935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of antihyperlipidemic drug management in clinical practice.
    Andrade SE; Saperia GM; Berger ML; Platt R
    Clin Ther; 1999 Nov; 21(11):1973-87. PubMed ID: 10890267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of lipid disorders in the elderly.
    Playford DA; Watts GF
    Drugs Aging; 1997 Jun; 10(6):444-62. PubMed ID: 9205850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.